PL3512537T3 - Immunoterapia limfocytami t - Google Patents

Immunoterapia limfocytami t

Info

Publication number
PL3512537T3
PL3512537T3 PL16769929.7T PL16769929T PL3512537T3 PL 3512537 T3 PL3512537 T3 PL 3512537T3 PL 16769929 T PL16769929 T PL 16769929T PL 3512537 T3 PL3512537 T3 PL 3512537T3
Authority
PL
Poland
Prior art keywords
cell immunotherapy
immunotherapy
cell
Prior art date
Application number
PL16769929.7T
Other languages
English (en)
Inventor
Di YU
Magnus Essand
Chuan Jin
Mohanraj RAMACHANDRAN
Jing Ma
Original Assignee
Elicera Therapeutics Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elicera Therapeutics Ab filed Critical Elicera Therapeutics Ab
Publication of PL3512537T3 publication Critical patent/PL3512537T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL16769929.7T 2016-09-15 2016-09-15 Immunoterapia limfocytami t PL3512537T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2016/071775 WO2018050225A1 (en) 2016-09-15 2016-09-15 T-cell immunotherapy
EP16769929.7A EP3512537B1 (en) 2016-09-15 2016-09-15 T-cell immunotherapy

Publications (1)

Publication Number Publication Date
PL3512537T3 true PL3512537T3 (pl) 2024-02-26

Family

ID=56979541

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16769929.7T PL3512537T3 (pl) 2016-09-15 2016-09-15 Immunoterapia limfocytami t

Country Status (6)

Country Link
US (1) US20190209615A1 (pl)
EP (1) EP3512537B1 (pl)
CN (1) CN110225760B (pl)
ES (1) ES2964694T3 (pl)
PL (1) PL3512537T3 (pl)
WO (1) WO2018050225A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
EP3781176A4 (en) * 2018-04-09 2022-05-25 The Trustees of the University of Pennsylvania METHODS AND COMPOSITIONS USING A VIRAL VECTOR FOR THE EXPRESSION OF A TRANSGENE AND AN EFFECTOR
CN115768890A (zh) * 2020-04-15 2023-03-07 加州理工学院 通过分子和物理启动对t细胞免疫疗法的热控制
CN112226408B (zh) * 2020-09-30 2024-04-02 西北农林科技大学 一种猪病原或外源性蛋白特异性抗原肽筛选和鉴定的方法
CN112285347B (zh) * 2020-09-30 2023-12-22 西北农林科技大学 一种猪血清样中病原抗体elisa检测试剂盒
WO2023010118A1 (en) * 2021-07-29 2023-02-02 Vor Biopharma Inc. Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same
CN113402620B (zh) * 2021-07-30 2021-12-10 中山大学 细胞因子联合嵌合抗原受体的融合蛋白及其应用
CN113402621B (zh) * 2021-08-02 2021-12-10 中山大学 含有嵌合抗原受体的融合蛋白及其应用
CN115980345A (zh) * 2022-08-30 2023-04-18 中国疾病预防控制中心传染病预防控制所 一种检测幽门螺旋杆菌的方法与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1279404A1 (en) * 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
EP1767214B1 (en) * 2005-09-23 2009-05-13 Gianfranco Del Prete Use of neurotrophil activating protein of helicobacter pylori (HP-NAP) and/or of its portions as adjuvants for the development of T helper type 1 (TH1) immune responses
CN100579578C (zh) * 2006-07-20 2010-01-13 中国人民解放军第三军医大学 幽门螺杆菌抗原重组疫苗
WO2013120497A1 (en) * 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
CN103990121B (zh) * 2013-12-06 2015-07-08 上海联合赛尔生物工程有限公司 抗原嵌合体、抗原组合物、疫苗及其制备方法和试剂盒
CN103923935B (zh) * 2014-04-22 2016-05-25 郑州大学 sIL-4R-NAP融合基因
WO2016113203A1 (en) * 2015-01-12 2016-07-21 Pieris Ag Engineered t cells and uses therefor
SG10201913583QA (en) * 2016-08-23 2020-02-27 Univ California Proteolytically cleavable chimeric polypeptides and methods of use thereof
JP2022529380A (ja) * 2019-04-26 2022-06-21 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル キメラ抗原受容体構築物およびｃａｒ－ｔ細胞におけるそれらの使用

Also Published As

Publication number Publication date
ES2964694T3 (es) 2024-04-09
EP3512537A1 (en) 2019-07-24
EP3512537B1 (en) 2023-11-01
WO2018050225A1 (en) 2018-03-22
CN110225760B (zh) 2023-11-07
US20190209615A1 (en) 2019-07-11
CN110225760A (zh) 2019-09-10
EP3512537C0 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
ZA202005298B (en) Combination tumor immunotherapy
IL263513A (en) Enhanced activated t-cell therapy (act).
AU365267S (en) Ring
TWD174459S (zh) 戒指
PL3188641T3 (pl) Zespół utrzymujący
EP3160497A4 (en) Conjugates for immunotherapy
EP3215182A4 (en) Combination immunotherapy
EP3512537C0 (en) T-CELL IMMUNOTHERAPY
PT3452507T (pt) Imunoterapia anti-tau
PL3186160T3 (pl) Obejma zaciskowa
GB201415044D0 (en) Clamp
PL3094345T3 (pl) Immunoterapia oparta na liposomach
GB201603056D0 (en) Ring clip
HUE043734T2 (hu) Bilincs
GB201419210D0 (en) Clamp assembly
GB201702268D0 (en) No details available
HUE038131T2 (hu) Bilincs elrendezés
GB201406428D0 (en) Clamp
EP3228877A4 (en) Clamping band
EP3142698A4 (en) Immunotherapy with binding agents
GB201417275D0 (en) Tripod Portion
GB201714637D0 (en) Anti-tumour immunotherapy
GB201702267D0 (en) No details available
AP2016001092S (en) A-3
GB201611746D0 (en) Snagg free